1. Expert Rev Anti Infect Ther. 2016;14(3):311-24. doi:
10.1586/14787210.2016.1138857. Epub 2016 Feb 5.

The role of solithromycin in the management of bacterial community-acquired

Van Bambeke F(1), Tulkens PM(1).

Author information: 
(1)a Pharmacologie cellulaire et moléculaire , Louvain Drug Research Institute,
Université catholique de Louvain , Brussels , Belgium.

The fluoroketolide solithromycin is 2-fold more potent in vitro than
telithromycin against pneumococci (including macrolide-resistant strains) and
Haemophilus influenzae and very active on pathogens causing atypical pneumonia.
In contrast, it is a 30-fold less potent inhibitor of nicotinic receptors
incriminated in telithromycin toxicity. In Phase II/III trials, oral
solithromycin once-daily (800 mg on day 1; 400 mg on days 2-5) proved effective
and safe when compared to respiratory fluoroquinolones for the treatment of
community-acquired bacterial pneumonia (CABP). A Phase III intravenous trial vs. 
moxifloxacin has been recently completed for the same indication. Solithromycin
may restore interest in ketolides as a first-line therapy for CAPB. Solithromycin
safety should nevertheless be confirmed in larger populations allowing for
detection of rare adverse events.

DOI: 10.1586/14787210.2016.1138857 
PMID: 26848612  [PubMed - indexed for MEDLINE]